Home » Stocks » SRPT

Sarepta Therapeutics, Inc. (SRPT)

Stock Price: $87.11 USD -1.82 (-2.05%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
After-hours: $87.10 -0.01 (-0.01%) Mar 3, 7:59 PM
Market Cap 7.18B
Revenue (ttm) 540.10M
Net Income (ttm) -554.13M
Shares Out 77.96M
EPS (ttm) -7.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $87.11
Previous Close $88.93
Change ($) -1.82
Change (%) -2.05%
Day's Open 88.36
Day's Range 86.86 - 91.62
Day's Volume 1,257,486
52-Week Range 77.01 - 181.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Forbes - 1 day ago

Despite A Q4 Miss Sarepta Therapeutics Stock Could See Higher Levels[Updated 3/2/2021] Sarepta Update Last month we talked about how Sarepta Therapeutics stock (NASDAQ: SRPT) seems to be a goo...

Zacks Investment Research - 1 day ago

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

Zacks Investment Research - 2 days ago

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -20.00% and 1.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t...

Benzinga - 2 days ago

Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 17.20% over the past year t...

GlobeNewsWire - 2 days ago

– Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference –

GlobeNewsWire - 5 days ago

CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021...

Benzinga - 5 days ago

Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.

GlobeNewsWire - 6 days ago

-- AMONDYS 45 is Sarepta's third RNA exon-skipping treatment for DMD approved in the U.S. ---- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately ---- Information for ...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management...

Forbes - 1 week ago

Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 r...

Other stocks mentioned: NBIX, VERX
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-ye...

Zacks Investment Research - 2 weeks ago

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 weeks ago

Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT...

Newsfile Corp - 3 weeks ago

Los Angeles, California--(Newsfile Corp. - February 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of invest...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - February 6, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT)....

PRNewsWire - 3 weeks ago

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such investors are...

GlobeNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the four winners of th...

PRNewsWire - 1 month ago

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therap...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2...

Forbes - 1 month ago

Sarepta Therapeutics stock, is a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases. SRPT stock is now at...

Zacks Investment Research - 1 month ago

Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.

Zacks Investment Research - 1 month ago

Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.

GlobeNewsWire - 1 month ago

-- Alliance will assess the use of Sarepta's proprietary gene editing technology and Genevant's proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have optio...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.

Zacks Investment Research - 1 month ago

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Seeking Alpha - 1 month ago

The biotech space remains one of my favorite sectors for outsized gains. With the potential for large gains needs to be balanced with far more volatility than seen in other sectors.

Seeking Alpha - 1 month ago

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

The Motley Fool - 1 month ago

Disappointing trial results caused a flock of analysts to drop their ratings on this biotech stock.

PRNewsWire - 1 month ago

NEW YORK, Jan. 9, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therape...

PRNewsWire - 1 month ago

NEW YORK, Jan. 8, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Sare...

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. ...

Benzinga - 1 month ago

Tenet Healthcare (NYSE: THC) shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to $60. Tenet is a Dallas-based healthcare provi...

Other stocks mentioned: CVS, TMO, THC
The Motley Fool - 1 month ago

The biotech announced disappointing results from a clinical study of its lead gene-therapy candidate.

InvestorPlace - 1 month ago

Shares of SRPT stock are getting hammered on Friday after Sarepta Therapeutics reported negative results from a treatment trial. The post SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Pl...

Schaeffers Research - 1 month ago

The shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have nearly halved this morning, down 49.8% at $84.90 at last check, after the company's experimental gene therapy to treat Duchene muscula...

Zacks Investment Research - 1 month ago

Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.

Benzinga - 1 month ago

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Ca...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management...

Market Watch - 1 month ago

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.

GlobeNewsWire - 1 month ago

-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- ...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, ...

Benzinga - 2 months ago

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (...

Other stocks mentioned: FOLD
Business Wire - 2 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SRPT #PrecisionOncology--Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

GlobeNewsWire - 2 months ago

-- Ian Estepan named chief financial officer -- Dallan Murray named chief commercial officer -- Louise Rodino-Klapac, Ph.D., named chief scientific officer -- Ty Howton, general counsel, to re...

Zacks Investment Research - 2 months ago

Sarepta's (SRPT) ongoing phase II study data supports continued dose escalation of SRP-5051 and suggests improved efficacy on lower doses compared to Exondys 51.

Seeking Alpha - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference (Transcript)

GlobeNewsWire - 2 months ago

-- Results from the multiple - ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than ...

About SRPT

Sarepta Therapeutics, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skip... [Read more...]

Industry
Biotechnology
IPO Date
Jun 3, 1997
CEO
Douglas Ingram
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
SRPT
Full Company Profile

Financial Performance

In 2020, SRPT's revenue was $540.10 million, an increase of 41.82% compared to the previous year's $380.83 million. Losses were -$554.13 million, -22.51% less than in 2019.

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is 129.00, which is an increase of 48.09% from the latest price.

Price Target
$129.00
(48.09% upside)
Analyst Consensus: Buy